What is the Buying Price of Glenmark Pharmaceuticals Share?

The Buying Price of Glenmark Pharmaceuticals share is 2177.2 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

How to buy Glenmark Pharmaceuticals Share at Choice?

To buy Glenmark Pharmaceuticals stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Glenmark Pharmaceuticals, choose your preferred order type, and place the trade.

What is the PE ratio of Glenmark Pharmaceuticals Shares?

The Price-to-earnings (P/E) ratio of Glenmark Pharmaceuticals shares is 45.28. You can compare it with the sector average for relative valuation.

What is the PB ratio of Glenmark Pharmaceuticals Shares?

The Price to Book (P/B) ratio Glenmark Pharmaceuticals shares is 5.87. Useful to assess the stock's value relative to its book value.

Is Glenmark Pharmaceuticals Overvalued?

To assess Glenmark Pharmaceuticals’s valuation compare Sector P/E, P/B which are 69.69 & 2.97 with sector averages, along with growth rates and financial metrics.

What is the Market Cap of Glenmark Pharmaceuticals?

The Market Cap of Glenmark Pharmaceuticals is 61649.59 CR. It indicates the company's size category and trading liquidity.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Share Price?

The 52 week high and low prices of Glenmark Pharmaceuticals share price is 2474 & 1380. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Which sector does Glenmark Pharmaceuticals belong to?

Glenmark Pharmaceuticals belongs to the Healthcare sector.

Glenmark Pharmaceuticals Share price

GLENMARK

Healthcare Large Cap

2177.2

7.40 (-0.34%)

NSE

BSE

Last updated on 3 Jun, 2026 | 14:41 IST

BUYSELL

Today's High

2222.00

Today's Low

2148.20

52 Week Low

1380.00

52 Week High

2474.00

Free Demat with Zero AMC*

Glenmark Pharmaceuticals Chart

ChartIQ

TradingView

Glenmark Pharmaceuticals Share Key Metrics

Volume

9.10 L

Market Cap

61649.59 CR

LTQ@LTP

4@2177.20

ATP

2167.94

Var Margin

15.88 %

Circuit Range

1966.2-2403

Delivery %

52.26 %

Value

197.35 CR

ASM/GSM

No

Market Lot

1

Summary

3 Jun, 2026 | 14:41 को, Glenmark Pharmaceuticals का शेयर प्राइस आज ₹2177.2 पर है, जो दिन के लिए 7.40% की -0.34 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹2148.20 और ₹2222.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹1380.00 से ₹2474.00 तक रही है। ट्रेडिंग गतिविधि के मामले में, Glenmark Pharmaceuticals ने 910306 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹282200809 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹216794 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 4,217720 रही। यह स्टॉक ₹1966.2-2403 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹197.35 CR है। दिन के लिए डिलीवरी परसेंटेज 52.26% रही। इसके अतिरिक्त, Glenmark Pharmaceuticals वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Glenmark Pharmaceuticals Fundamentals

P/E Ratio

45.28

P/B Ratio

5.87

Div. Yield

0.11

Sector P/E

69.69

Sector P/B

2.97

Sec. Div. Yield

0.55

Glenmark Pharmaceuticals Resistance and Support

Pivot 2188.57

Resistance

First Resistance

2232.84

Second Resistance

2281.07

Third Resistance

2325.34

Support

First Support

2140.34

Second Support

2096.07

Third Support

2047.84

Glenmark Pharmaceuticals Futures & Options

Glenmark Pharmaceuticals Ltd Share Price

2177.2

-7.4 (-0.34%)

Glenmark Pharmaceuticals Option Chain

View Price, OI, Greeks & More...

View All

30JUN26

2199.20

-6.00 (0.27%)

28JUL26

2188.10

-28.70 (1.29%)

25AUG26

2255.50

47.50 (2.15%)

GLENMARK|30JUN26 CE 2160.00

96.95 -2.5 (-2.51%)

GLENMARK|30JUN26 PE 2180.00

63.55 2.8 (4.61%)

Glenmark Pharmaceuticals Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

46.65%

Mutual Fund

16.8%

Insurance

1%

Foreign Institutional Investors

20.35%

Domestic Institutional Investors

1.52%

Retail

13.68%

Others

0%

Total Promoters

MAR '26

46.65%

Glenmark Pharmaceuticals Corporate Actions

Date	Agenda
2026-05-29	Audited Results & Final Dividend
2026-01-30	Quarterly Results

Glenmark Pharmaceuticals News

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals reported strong Q4 FY26 and full-year FY26 results with significant revenue growth. The company also secured a landmark USD 1.925 billion licensing deal with AbbVie and made progress in its key business segments.

May 29 2026 22:12:28

Glenmark Pharmaceuticals Ltd - 532296 - Transfer Of Company''s Nebulizer Brand

Glenmark Pharmaceuticals transferred its Nebulizer brands and IP portfolio to its wholly-owned subsidiary, Glenmark Healthcare Limited (GHL), for a cash consideration of Rs. 223 crore. This internal restructuring aims to enhance strategic focus and operational agility.

May 29 2026 20:52:22

Glenmark Pharmaceuticals Ltd - 532296 - Corporate Action-Board to consider Dividend

Glenmark Pharma board recommended a final dividend of ₹2.50 per equity share for FY26. This dividend, representing 250% of face value, awaits shareholder approval.

May 29 2026 20:23:37

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend

Glenmark Pharma reported robust financial results for FY26, with consolidated revenue rising 27.48% YoY to ₹16,982.51 crores and net profit increasing 30.06% YoY to ₹1,361.95 crores. The board also recommended a final dividend of ₹2.5 per share for the fiscal year.

May 29 2026 20:15:20

Glenmark Pharmaceuticals Ltd - 532296 - Settlement Agreement: Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015,

Glenmark Pharmaceuticals' US subsidiary, Glenmark USA, has reached a settlement agreement for $29.628 million with state attorneys general to resolve antitrust lawsuits related to alleged price-fixing. The settlement aims to resolve long-standing litigation in the US.

May 23 2026 09:31:57

Glenmark Pharmaceuticals Limited

Glenmark Pharma's US subsidiary, Glenmark USA, settled multi-year antitrust and consumer protection lawsuits for $29.628 million, payable in annual installments over 5 years. The amount is fully provisioned in financials, with no significant impact on the company's financial position.

May 23 2026 09:26:28

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharma, announced ISB 2301, a first-in-class multispecific immune cells activator for solid tumors. The drug candidate, developed using IGI's BEAT® platform, targets three tumor-associated antigens and activates both T and NK cells. IGI plans to submit an IND application this year, with clinical studies commencing in 2027. This represents a significant advancement in IGI's oncology pipeline.

May 20 2026 16:23:49

Glenmark Pharmaceuticals Limited

Glenmark Pharma's subsidiary Ichnos Glenmark Innovation (IGI) has announced a new development candidate, ISB 2301. This first-in-class multispecific antibody targets solid tumors and is expected to enter clinical studies by 2027, representing a significant advancement in oncology R&D.

May 20 2026 16:23:44

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals board is scheduled to meet on May 29, 2026. The agenda includes the consideration and approval of the audited financial results for the quarter and year ended March 31, 2026, along with a potential dividend recommendation.

May 19 2026 16:52:14

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results And Recommending Dividend, If Any, On Equity Shares For The Year Ended March 31, 2026.

Glenmark Pharmaceuticals' Board of Directors will convene on May 29, 2026. The agenda includes considering and approving the standalone and consolidated audited financial results for Q4 and full-year FY26, alongside a recommendation for dividend, if any.

May 19 2026 16:48:23

Name	Position
Harish Kuber	Company Secretary & Compliance Officer
Glenn Saldanha	Chairman & Managing Director

Glenmark Pharmaceuticals Similar Stocks

Aurobindo Pharma Ltd.

1444.60

15.40 (1.08%)

Laurus Labs Ltd.

1394.80

12.20 (0.88%)

Fortis Healthcare Ltd.

932.25

2.85 (0.31%)

Biocon Ltd.

412.80

-4.00 (0.96%)

Alkem Laboratories Ltd.

5271.00

32.00 (0.61%)

Abbott India Ltd.

26285.00

-10.00 (0.04%)

Anthem Biosciences Ltd.

752.70

-2.90 (0.38%)

Narayana Hrudayalaya Ltd.

1972.50

38.30 (1.98%)

Ipca Laboratories Ltd.

1552.30

44.60 (2.96%)

Gland Pharma Ltd.

2236.90

-40.10 (1.76%)

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals शेयर का खरीद मूल्य 2177.2 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Glenmark Pharmaceuticals शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Glenmark Pharmaceuticals शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 45.28 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Glenmark Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 5.87 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Glenmark Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.97 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Glenmark Pharmaceuticals का मार्केट कैप 61649.59 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Glenmark Pharmaceuticals शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 2474.00 और 1380.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।